Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Harrow Health Inc.

harrowinc.com

Latest From Harrow Health Inc.

Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public

October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.

Financing Business Strategies

IPO Update: Returns Sag As Seven More Biopharmas Go Public In September

The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.

Financing Business Strategies

Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows

The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.

Financing Business Strategies

Aquinox, Astellas Mull Options As Rosiptor Fails

Astellas’ late-stage bet on Aquinox’s urology drug now looks highly unlikely to pay off following the molecule’s “definitive” failure in a Phase III trial, which is also forcing the originator to consider its business  and R&D options.

Commercial Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Topical Delivery
  • Therapeutic Areas
  • Gynecological, Urological
  • Neurology, Nervous System
  • Ophthalmic
  • Otolaryngology
  • Alias(es)
  • Transdel Pharmaceuticals Inc.
  • Trans-Pharma Corp.
  • Imprimis Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Harrow Health Inc.
  • Senior Management
  • Mark L Baum, CEO
    Andrew R Boll, CFO
    Gary Seelhorst, VP, Bus. Dev.
    John Saharek, Chief Commercial Officer
  • Contact Info
  • Harrow Health Inc.
    Phone: (844) 446-6979
    12264 El Camino Real
    Ste. 350
    San Diego, CA 92130
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register